- Home
- VLGEA vs BCYC Comparison
VLGEA vs BCYC Comparison
Compare VLGEA & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VLGEA
- BCYC
- Stock Information
- Founded
- VLGEA 1937
- BCYC 2009
- Country
- VLGEA United States
- BCYC United Kingdom
- Employees
- VLGEA N/A
- BCYC N/A
- Industry
- VLGEA Food Chains
- BCYC Biotechnology: Pharmaceutical Preparations
- Sector
- VLGEA Consumer Staples
- BCYC Health Care
- Exchange
- VLGEA Nasdaq
- BCYC Nasdaq
- Market Cap
- VLGEA 541.1M
- BCYC 492.1M
- IPO Year
- VLGEA N/A
- BCYC 2019
- Fundamental
- Price
- VLGEA $39.10
- BCYC $6.90
- Analyst Decision
- VLGEA
- BCYC Buy
- Analyst Count
- VLGEA 0
- BCYC 11
- Target Price
- VLGEA N/A
- BCYC $22.91
- AVG Volume (30 Days)
- VLGEA 35.3K
- BCYC 233.2K
- Earning Date
- VLGEA 10-07-2025
- BCYC 10-30-2025
- Dividend Yield
- VLGEA 2.54%
- BCYC N/A
- EPS Growth
- VLGEA 12.55
- BCYC N/A
- EPS
- VLGEA 3.80
- BCYC N/A
- Revenue
- VLGEA $2,299,253,000.00
- BCYC $19,281,000.00
- Revenue This Year
- VLGEA N/A
- BCYC N/A
- Revenue Next Year
- VLGEA N/A
- BCYC $0.27
- P/E Ratio
- VLGEA $9.81
- BCYC N/A
- Revenue Growth
- VLGEA 3.94
- BCYC N/A
- 52 Week Low
- VLGEA $28.33
- BCYC $6.10
- 52 Week High
- VLGEA $40.15
- BCYC $28.67
- Technical
- Relative Strength Index (RSI)
- VLGEA 70.34
- BCYC 39.17
- Support Level
- VLGEA $36.85
- BCYC $6.84
- Resistance Level
- VLGEA $39.43
- BCYC $7.32
- Average True Range (ATR)
- VLGEA 0.73
- BCYC 0.36
- MACD
- VLGEA 0.29
- BCYC 0.01
- Stochastic Oscillator
- VLGEA 91.27
- BCYC 14.56
About VLGEA Village Super Market Inc.
Village Super Market Inc operates a chain of ShopRite supermarkets, a few of which are in northern New Jersey, southern New Jersey, Maryland, and in northeastern Pennsylvania. The company is a member of Wakefern Food Corporation (Wakefern), a retailer-owned food cooperative and owner of the ShopRite name. It consists of one operating segment, the retail sale of food and nonfood products.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.